Hormonal Replacement Therapy in Women With Parkinson Disease and Levodopa-Induced Dyskinesia: A Crossover Trial : Clinical Neuropharmacology

Journal Logo

Original Articles

Hormonal Replacement Therapy in Women With Parkinson Disease and Levodopa-Induced Dyskinesia

A Crossover Trial

Nicoletti, Alessandra MD*; Arabia, Gennarina MD†; Pugliese, Pierfrancesco MD†; Nicoletti, Giuseppe MD†; Torchia, Giusi TNFP†; Condino, Francesca PhD‡; Morgante, Letterio MD§; Quattrone, Aldo MD‡§; Zappia, Mario MD*

Author Information
Clinical Neuropharmacology 30(5):p 276-280, September 2007. | DOI: 10.1097/wnf.0b013e318050c9f9

Abstract

Eleven postmenopausal women with Parkinson disease and levodopa-induced peak-dose dyskinesias underwent a double-blind, placebo-controlled, crossover study. The active treatment consisted of estrogen replacement therapy for 12 weeks, followed by medroxyprogesterone acetate for 2 weeks. Estrogen replacement therapy-medroxyprogesterone acetate administration significantly improved peak-dose dyskinesia without worsening motor disability, thus suggesting a possible benefit on dyskinesias in postmenopausal women with Parkinson disease.

© 2007 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid